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SUPPLEMENTARY DATA 







All patients with 
PC excluding main 
nmCRPC cohort 
(n=36,556) 




Age at, median (IQR) 
PC diagnosis 75.6 (69.2–80.4) 74.7 (68.5–79.8) 72.7 (65.9–79.6) 72.8 (65.9–79.6) 
Initiation of ADT 76.6 (70.9–81.3) 76.0 (70.0–80.8) 74.3 (68.1–79.2) 76.2 (70.4–81.1) 
nmCRPC inclusion 79.5 (73.6–84.6) 78.7 (72.6–83.6) N/A N/A 
Development of 
metastases 78.1 (72.3–84.3) 78.5 (72.7–85.0) 75.4 (68.8–81.5) 75.5 (68.9–81.6) 
Death 83.2 (77.0–88.4) 82.4 (76.4–87.8) 82.0 (75.8–87.1) 82.0 (75.9–87.2) 
Treatment, n (%) 
ADT 1,465 (100.0) 470 (100.0) 15,446 (42.3) 16,441 (43.8) 
Orchidectomy <5 (<0.1)a <5 (<0.1)a >215 (~0.6) >215 (~0.6)
Prostatectomy 18 (1.2) 7 (1.5) 4,343 (11.9) 4,354 (11.6)
Radiotherapy 189 (12.9) 140 (29.8) 5,152 (14.1) 5,201 (13.9)
PSA doubling time 
≤10 months 952 (65.0) 323 (68.7) N/A N/A 







All patients with 
PC excluding main 
nmCRPC cohort 
(n=36,556) 





≤6 187 (12.8) 48 (10.2) 9,220 (25.2) 9,359 (24.9) 
7 269 (18.4) 90 (19.1) 6,457 (17.7) 6,636 (17.7) 
8–10 347 (23.7) 134 (28.5) 4,223 (11.6) 4,436 (11.8) 
Unknown 662 (45.2) 198 (42.1) 16,656 (45.3) 17,120 (45.6) 
TNM score 
Tany N0 M0 64 (4.4) 11 (2.3) 5,536 (15.1) 5,589 (14.9) 
Tany N1–2 M0 N/A N/A 269 (0.7) 269 (0.7) 
Tany Nany M1 N/A N/A 619 (1.7) 619 (1.6) 
Other N/A N/A 84 (0.2) 84 (0.2) 
Unknown 1,401 (95.6) 459 (97.7) 30,048 (82.2) 30,990 (82.5) 
Time in months, median 
(IQR) 
From PC diagnosis to 
nmCRPC 37.4 (20.3–66.9) 36.9 (20.5–64.2) N/A N/A 
Duration of follow-up from 
nmCRPC diagnosis 37.6 (19.5–61.3) 41.1 (22.0–66.9) N/A N/A 
aThese results are presented as ‘<5’ to ensure patient anonymity. ADT: androgen deprivation therapy; IQR: interquartile range; N/A: not available; nmCRPC: non-metastatic 
castration-resistant prostate cancer; PC: prostate cancer; PSA: prostate-specific antigen; TNM: tumor, node, metastasis. 
Figure S1: Patient flow diagram 
ADT: androgen deprivation therapy; nmCRPC: non-metastatic castration-resistant prostate cancer; PSA: 
prostate-specific antigen; TNM: tumor, node and metastasis code; WCISU: Welsh Cancer Incidence and 
Surveillance Unit. 
DEFINITION OF VARIABLES 
Date of primary malignant prostate cancer diagnosis 
The data source was searched to identify all individuals where the first occurrence of 
a primary malignant prostate cancer (PC) diagnosis code (International Classification 
of Diseases [ICD]-10 code of C61% or Read code v2 of B46%) was between 01 
January 2000 and 31 December 2015. The diagnosis date was the entry point to the 
overall primary malignant PC cohort (including individuals with cancers of all disease 
states). Welsh Cancer Incidence and Surveillance Unit (WCISU) was the primary data 
source as it contains a definitive diagnosis date. Where individuals were present in 
multiple datasets, the following priority sequence was used to determine date of 
diagnosis: 
1. WCISU first diagnosis date
2. Wales Primary Care GPs (WLGP) first event date 
3. Patient Episode Dataset for Wales (PEDW) first admission date – the reason 
for this is that PEDW records the dates on which individuals were admitted to 
hospital for treatment, but this is not necessarily the same as the date of 
diagnosis. 
Diagnosis of other primary cancer  
Cases were flagged to indicate patients diagnosed with another primary malignant  
cancer. The earliest and latest dates of primary malignant cancer diagnosis (other  
than PC) were included in the cohort dataset, to ensure that individuals undergoing  
treatment for other cancer could be excluded if required. All cancer codes from the  
primary malignant cancers ICD-10 chapter (for ICD-10 codes) and all primary cancer  
codes from the general practitioner (GP) Quality and Outcomes Framework (QOF)  
cancer indicator (for Read v2 codes) were flagged.  
Diagnosis of secondary/metastatic cancer (including treatments indicating  
secondary/metastatic cancers)  
Cases were flagged to show the earliest and latest dates of a diagnosis with  
secondary/metastatic cancer. All cancer codes from the secondary malignant cancers  
ICD-10 chapter (for ICD-10 codes) and all secondary cancer codes from the GP  
Quality and QOF cancer indicator (for Read v2 codes) were flagged. PEDW was 
searched for ICD morphology codes (used in PEDW until December 2016).  
Morphology codes are identified in PEDW as any 6-character diagnosis code (any  
position) where the first two characters are ‘M8’ or ‘M9’; metastatic morphology  
codes are defined as those where the sixth character is a ‘6’. The earliest and latest  
date of a morphology code indicating metastatic disease was recorded. Flags were  
created for individuals with codes for treatments indicating metastatic disease, with  
variables created for the earliest and latest treatment date.  
Diagnosis of non-metastatic cancer  
PEDW was searched for non-metastatic morphology codes (as above but where the  
sixth character is ‘0’ [benign], ‘1’ [uncertain whether benign or malignant], ‘2’ [in  
situ] or ‘3’ [malignant]). The earliest and latest date of a non-metastatic morphology  
code was recorded.  
Androgen Deprivation Therapy  
To qualify as ‘on’ Androgen Deprivation Therapy (ADT) for the purposes of selecting  
the non-metastatic castration resistance PC (nmCRPC) cohort, there should be a gap  
of no more than six months between medication prescription dates as recorded in  
the GP history. The start and end dates for the ADT continuous treatment period  
were defined as the date of first ADT prescription and the end date of the last  
prescription plus six months.  
Non-metastatic disease  
Metastatic disease was identified by the presence or absence of a number of codes.  
Any individuals with a Node (N) or Metastasis (M) code which indicated metastatic  
disease at time of diagnosis (according to the WCISU dataset) were excluded, as  
were any individuals with a WCISU morphology code indicating metastasis. In  
addition, the PEDW dataset was searched for morphology codes indicating metastatic  
or non-metastatic disease. Two levels of confidence were derived from these codes:  
the broader definition included anyone with no metastatic code in their history on or  
before the nmCRPC entry date (the main nmCRPC cohort); the more stringent  
definition included those individuals who had a definitive non-metastatic code on or  
after the nmCRPC date (the stringent nmCRPC cohort) in the absence of any codes  
indicating metastatic disease at this time.  
Prostate specific antigen test results  
The SPARTAN trial definition was adopted for a rising prostate specific antigen (PSA)  
concentration meeting the criteria for PSA progression; three PSA test results, with at  
least 1 week between each test, with increasingly high concentrations and with the  
latest PSA concentration ≥2 ng/ml [9]. The first date upon which PSA concentration  
rose (e.g. the second PSA test date) was adopted as the nmCRPC cohort entry date.  
All PSA test results had to be during ADT treatment periods.  
Calculation of PSA doubling time  
PSA doubling time (PSADT) was calculated using the same three PSA values used to  
determine nmCRPC diagnosis. The PSADT was calculated as the gradient of the  
linear regression of the log (base 2) of the three PSA values. No nadir correction was  
required. Arlen et al. suggested that a minimum interval of 4 weeks was required  
between PSA tests where nmCRPC diagnosis specified a 1 week interval [26].  
Consequently, for consistency, the 1 week specification was maintained for the study  
cohort.  
Survival to metastasis or death  
Survival to metastasis or death was defined as the time from nmCRPC inclusion to  
the first detection of metastasis or death from any cause, whichever occurred first.  
Follow-up time  
Data for the PC cohort was extracted from WDS, to calculate follow-up time in SAIL  
and identify individuals lost to follow up.  
DATASETS  
Metadata are available in the references for each dataset.  
WCISU is the national cancer registry of Wales and contains details of all individuals  
resident in Wales who have been diagnosed with cancer [27]. The WCISU dataset  
has an excellent level of coverage in terms of capturing individuals diagnosed with  
cancer, and clinical coding (ICD10) is 100% complete, but lacks detail about the  
ongoing patient journey, treatments over time or disease progression.  
PEDW contains details about inpatient admissions using the ICD10 and Office of  
Population Censuses and Surveys Version 4 (OPCS4) standard coding systems [28].  
It can be used to track a patient journey longitudinally as it contains a full history of  
contacts with inpatient care.  
WLGP contains details of all contacts between individuals and their GP practice:  
observations, prescriptions, test results, symptoms, diagnoses etc. coded using Read  
codes (primarily v2) [29].  
ADDE contains details of all deaths of individuals resident in Wales or resident  
elsewhere who died in Wales [30].  
WDS provides the start and end dates of periods of registration with Welsh GP  
practices [16]. It is used to calculate follow-up periods, person-years at risk and to  
identify when individuals become lost to follow up.  
